Astrazeneca PLC (NYSE:AZN) – Stock analysts at Leerink Swann cut their FY2018 EPS estimates for shares of Astrazeneca PLC in a report released on Friday. Leerink Swann analyst S. Fernandez now anticipates that the company will post earnings of $1.70 per share for the year, down from their previous estimate of $1.72. Leerink Swann currently has a “Outperform” rating and a $36.00 target price on the stock. Leerink Swann also issued estimates for Astrazeneca PLC’s FY2019 earnings at $2.08 EPS and FY2020 earnings at $2.43 EPS.
AZN has been the subject of several other research reports. HSBC Holdings plc lowered shares of Astrazeneca PLC from a “hold” rating to a “reduce” rating in a report on Friday, April 7th. Barclays PLC restated an “overweight” rating on shares of Astrazeneca PLC in a report on Thursday. BidaskClub lowered shares of Astrazeneca PLC from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Credit Suisse Group upgraded shares of Astrazeneca PLC from an “underperform” rating to a “neutral” rating in a report on Friday, May 12th. Finally, Jefferies Group LLC restated a “hold” rating on shares of Astrazeneca PLC in a report on Monday, April 10th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $34.13.
WARNING: This piece was posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/2722417/fy2018-eps-estimates-for-astrazeneca-plc-decreased-by-leerink-swann-azn.html.
Astrazeneca PLC (AZN) opened at 33.87 on Monday. The firm has a market cap of $85.76 billion, a PE ratio of 25.37 and a beta of 0.77. The company’s 50-day moving average is $34.36 and its 200-day moving average is $30.51. Astrazeneca PLC has a one year low of $25.55 and a one year high of $35.60.
Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings data on Thursday, April 27th. The company reported $0.99 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.38 by $0.61. The firm had revenue of $5.41 billion during the quarter, compared to analysts’ expectations of $5.40 billion. Astrazeneca PLC had a net margin of 15.21% and a return on equity of 35.65%. The business’s revenue for the quarter was down 11.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.95 earnings per share.
Institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. purchased a new position in Astrazeneca PLC during the fourth quarter worth about $2,014,000. Norges Bank purchased a new position in Astrazeneca PLC during the fourth quarter worth about $8,217,000. Vident Investment Advisory LLC increased its position in Astrazeneca PLC by 8.7% in the fourth quarter. Vident Investment Advisory LLC now owns 26,658 shares of the company’s stock worth $728,000 after buying an additional 2,144 shares in the last quarter. Dodge & Cox purchased a new position in Astrazeneca PLC during the fourth quarter worth about $1,355,443,000. Finally, Becker Capital Management Inc. increased its position in Astrazeneca PLC by 7.3% in the fourth quarter. Becker Capital Management Inc. now owns 1,286,487 shares of the company’s stock worth $35,147,000 after buying an additional 87,515 shares in the last quarter. 14.01% of the stock is currently owned by hedge funds and other institutional investors.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.